Longeveron Inc. (LGVN)
NASDAQ (CM) NASDAQ (CM) Primary 
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
Longeveron Inc. ( LGVN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Than Powell - Interim CEO & Director Nataliya Agafonova - Chief Medical Officer Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Lisa Locklear - CFO, Executive VP & Treasurer Joshua Hare - Co-Founder, Chief Science Officer & Executive Chairman Conference Call Participants Derek Cole Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Boobalan Pachaiyappan - ROTH Capital Partners, LLC, Research Division Michael Okunewitch - Maxim Group LLC, Research Division Presentation Operator Greetings, and welcome to the Longeveron 2025 Q3 Financial Results and Business Update Call.
Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript
Longeveron Inc. (NASDAQ:LGVN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Joshua Michael Hare - Co-Founder, Chief Science Officer & Chairman Lisa A. Locklear - CFO, Executive VP & Treasurer Mohamed Wa'el Ahmed Hashad - CEO & Director Nataliya Agafonova - Chief Medical Officer Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners, LLC, Research Division Michael Okunewitch - Maxim Group LLC, Research Division Raghuram Selvaraju - H.C.
Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript
Longeveron Inc. (NASDAQ:LGVN ) Q4 2024 Earnings Conference Call February 28, 2025 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners Ram Selvaraju - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Longeveron 2024 and Full Year Financial Results Conference Call.
Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript
Longeveron, Inc. (NASDAQ:LGVN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Partners Operator Ladies and gentlemen, greetings and welcome to the Longeveron Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript
Longeveron, Inc. (NASDAQ:LGVN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - CMO Lisa Locklear - CFO Joshua Hare - Co-Founder, Chief Science Officer & Chairman Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, and welcome to Longeveron's 2024 Second Quarter Financial Results Conference Call.
The Top 3 Small-Cap Stocks to Buy Now: Summer 2024
Small-cap stocks are back in favor. After languishing behind their larger brethren for years, small-cap stocks are roaring ahead as investors rotate into the sector once more.
Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates
Longeveron (NASDAQ: LGVN ) jumped after publishing a press release stating that Phase 2a results for its Alzheimer's treatment met primary endpoints. Lomecel-B is a treatment for mild cases of Alzheimer's disease.
LGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track Designation
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company received fast-track designation for its mild Alzheimer's Disease treatment. This has the Food and Drug Administration (FDA) granting this designation to Lomecel-B.
Longeveron stock opened 100% up on Wednesday: explore why
Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company's investigational treatment for Alzheimer's disease.
Why Is Longeveron (LGVN) Stock Up 53% Today?
Longeveron (NASDAQ: LGVN ) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company announced a new designation from the Food and Drug Administration (FDA). This has the FDA granting Longeveron's Lomecel-B the Regenerative Medicine Advanced Therapy (RMAT) designation.
